-Advertisement-
-Advertisement-
Presbyopia
CSF-1 eye drops show promise in treating presbyopia
Data presented at ASCRS 2023 suggests that CSF-1 (0.4% pilocarpine HCl ophthalmic solution) could be an effective treatment for presbyopia. The Phase 3 clinical trials, NEAR-1 and NEAR-2, which evaluated the safety and efficacy of CSF-1 in treating presbyopia, enrolled 613 participants between the ages of 45-64 years old with...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Videos
12 Dec, 2022
Mark Dlugoss: Vision correction has evolved over the years from...
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved